IL17A and systemic lupus erythematosus: Treatment with low-dose recombinant human IL-2selectively modulated the abundance of regulatory T(Treg) cells, follicular helper T (T FH) cells, and IL-17-producing helper T (TH 17) cells, but not TH 1 or TH 2cells, accompanied by marked reductions of diseaseactivity in patients with SLE.